KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Convertible Debt: 2009-2024

Historic Convertible Debt for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $595.1 million.

  • Biomarin Pharmaceutical's Convertible Debt rose 0.34% to $596.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.7 million, marking a year-over-year increase of 0.34%. This contributed to the annual value of $595.1 million for FY2024, which is 45.25% down from last year.
  • As of FY2024, Biomarin Pharmaceutical's Convertible Debt stood at $595.1 million, which was down 45.25% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Convertible Debt registered a high of $1.1 billion during FY2023, and its lowest value of $595.1 million during FY2024.
  • Over the past 3 years, Biomarin Pharmaceutical's median Convertible Debt value was $1.1 billion (recorded in 2022), while the average stood at $921.7 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Convertible Debt rose by 26.77% in 2020, and later crashed by 45.25% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Convertible Debt (Yearly) stood at $1.1 billion in 2020, then grew by 0.37% to $1.1 billion in 2021, then climbed by 0.37% to $1.1 billion in 2022, then grew by 0.36% to $1.1 billion in 2023, then crashed by 45.25% to $595.1 million in 2024.